Cancer: Breast | Study Type: Treatment
https://www.facingourrisk.org/research-clinical-trials/study/300/study-of-a-new-investigationai-inhibitor-to-treat-people-with-advanced-solid-tumors
Clinicaltrials.gov identifier:
NCT05932862 (https://clinicaltrials.gov/show/NCT05932862)
Treatment
Treatment study for people with advanced solid tumors
https://www.facingourrisk.org/research-clinical-trials/study/304/olaparib-with-cediranib-or-ceralasertib-for-people-with-advanced-or-metastatic-breast-cancer-and-with-a-brca1-or-brca2-mutation
Clinicaltrials.gov identifier:
NCT04090567 (https://clinicaltrials.gov/show/NCT04090567)
Treatment
This study will examine how Olaparib in combination with the drugs Cediranib or Ceralasertib works for patients with advanced breast cancer who have BRCA1 or BRCA2 genetic mutation and who were previously treated with a PARP inhibitor
https://www.facingourrisk.org/research-clinical-trials/study/231/immunotherapy-and-parp-inhibitor-for-advanced-or-metastatic-breast-ovarian-or-pancreatic-cancer-with-a-brca-mutation
Clinicaltrials.gov identifier:
NCT04673448 (https://clinicaltrials.gov/show/NCT04673448)
Treatment
Treatment study for people with advanced breast, ovarian or pancreatic cancer and an inherited or tumor BRCA mutation
https://www.facingourrisk.org/research-clinical-trials/study/311/study-of-a-new-treatment-called-onm-501-alone-and-in-combination-with-cemiplimab-in-people-with-triple-negative-breast-cancer-advanced-solid-tumors-and-lymphomas
Clinicaltrials.gov identifier:
NCT06022029 (https://clinicaltrials.gov/show/NCT06022029)
Treatment
Study of a new drug called ONM-501 for people with triple negative breast cancer, advanced solid tumors or lymphomas
https://www.facingourrisk.org/research-clinical-trials/study/285/treatment-study-for-people-with-stage-2-or-3-triple-negative-breast-cancer-at-high-risk-for-recurrence
Clinicaltrials.gov identifier:
NCT04674306 (https://clinicaltrials.gov/show/NCT04674306)
Treatment
Treatment study for people with stage 2 or 3 triple-negative breast cancer at high risk for recurrence.
https://www.facingourrisk.org/research-clinical-trials/study/282/study-of-the-parp-inhibitor-azd9574-alone-and-combined-with-other-cancer-medicines-to-treat-people-with-advanced-solid-cancers-certis1-study
Clinicaltrials.gov identifier:
NCT05417594 (https://clinicaltrials.gov/show/NCT05417594)
Treatment
Treatment study for people with advanced breast, ovarian, pancreatic or prostate cancer or gliomas
https://www.facingourrisk.org/research-clinical-trials/study/263/a-randomized-study-of-robotic-assisted-nipple-sparing-mastectomy-vs-open-surgery-nipple-sparing-mastectomy-for-early-stage-breast-cancer
Clinicaltrials.gov identifier:
NCT05720039 (https://clinicaltrials.gov/show/NCT05720039)
Treatment
Nipple sparing mastectomy with reconstruction for women with early-stage breast cancer
https://www.facingourrisk.org/research-clinical-trials/study/262/tapur-study-testing-fda-approved-drugs-targeting-tumor-gene-abnormalities-in-people-with-advanced-stage-cancer
Clinicaltrials.gov identifier:
NCT02693535 (https://clinicaltrials.gov/show/NCT02693535)
Treatment
Cancer treatment study for people with advanced solid tumors
https://www.facingourrisk.org/research-clinical-trials/study/230/treating-metastatic-solid-tumors-with-an-inherited-or-acquired-gene-mutation-using-the-parp-inhibitor-talazoparib
Clinicaltrials.gov identifier:
NCT04550494 (https://clinicaltrials.gov/show/NCT04550494)
Treatment
Treatment study for people with advanced solid tumors
https://www.facingourrisk.org/research-clinical-trials/study/204/nuv-868-alone-and-in-combination-with-parp-inhibitors-in-patients-with-advanced-solid-tumors
Clinicaltrials.gov identifier:
NCT05252390 (https://clinicaltrials.gov/show/NCT05252390)
Treatment
Treatment study for people with advanced solid tumors, including triple-negative breast, ovarian, pancreatic and prostate cancer
https://www.facingourrisk.org/research-clinical-trials/study/117/sharon-a-clinical-trial-for-metastatic-cancer-with-an-inherited-brca-or-palb2-mutation-using-chemotherapy-and-patients-own-stem-cells
Clinicaltrials.gov identifier:
NCT04150042 (https://clinicaltrials.gov/show/NCT04150042)
Treatment
Advanced pancreatic cancer or stage 4 breast cancer in people with a BRCA1 or BRCA2 mutation
https://www.facingourrisk.org/research-clinical-trials/study/158/treating-early-stage-breast-cancer-with-a-parp-inhibitor-niraparib-and-immunotherapy-dostarlimab-in-people-with-a-brca-or-palb2-mutation
Clinicaltrials.gov identifier:
NCT04584255 (https://clinicaltrials.gov/show/NCT04584255)
Treatment
Treatment before surgery for people with early-stage breast cancer & a BRCA1, BRCA2 or PALB2 mutation
https://www.facingourrisk.org/research-clinical-trials/study/176/investigational-parp-inhibitor-azd5305-alone-or-combined-with-other-anti-cancer-agents-in-people-with-advanced-solid-tumors-petra
Clinicaltrials.gov identifier:
NCT04644068 (https://clinicaltrials.gov/show/NCT04644068)
Treatment
Advanced ovarian, breast, prostate or pancreatic cancer
https://www.facingourrisk.org/research-clinical-trials/study/157/treatment-with-atr-inhibitor-for-advanced-or-metastatic-solid-tumors
Clinicaltrials.gov identifier:
NCT04657068 (https://clinicaltrials.gov/show/NCT04657068)
Treatment
Advanced solid tumors
https://www.facingourrisk.org/research-clinical-trials/study/100/talazoparib-for-people-with-metastatic-breast-cancer-who-have-acquired-somatic-brca-mutations
Clinicaltrials.gov identifier:
NCT03990896 (https://clinicaltrials.gov/show/NCT03990896)
Treatment
https://www.facingourrisk.org/research-clinical-trials/study/102/a-randomized-study-of-an-ehealth-delivery-alternative-for-cancer-genetic-testing-for-hereditary-predisposition-in-metastatic-breast-ovarian-prostate-and-pancreatic-cancer-patients-e-reach
Clinicaltrials.gov identifier:
NCT04353973 (https://clinicaltrials.gov/show/NCT04353973)
Treatment
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.